Thryv Therapeutics Inc. to Participate in 34th Piper Sandler Annual Healthcare Conference and in RBC Capital Markets Healthcare Private Company Virtual Conference

MONTREAL, Nov. 17, 2022 /PRNewswire/ - Thryv Therapeutics Inc., a biopharmaceutical company focused on a precision medicine approach to treat Long QT Syndromes via SGK1 inhibition and resistant cancers, will participate in a fireside chat and host investor meetings at the upcoming 34^th Piper Sandler Annual Healthcare Conference, and will participate in a fireside chat at the upcoming 2022 RBC Capital Markets Healthcare Private Company Conference.  Mr. Paul F. Truex will provide a full update on Thryv's progress to date with the development of a number of highly potent SGK1 inhibitors for all major forms of Long QT Syndrome, Atrial Fibrillation and resistant cancers.

• Piper Sandler 34^th Annual Healthcare Conference
  Location: New York, NY
  Fireside Chat: Tuesday, November 29^th, 2022 at 11:10 a.m. ET
  1x1 Meetings: Tuesday, November 29^th, 2022
  
  
• RBC Capital Markets Healthcare Private Company Virtual Conference
  Virtual Fireside Chat: Wednesday, December 14^th, 2022

Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.) is a privately owned pharmaceutical company pioneering a precision medicine approach through the inhibition of Serum and Glucocorticoid induced Kinase (SGK1) to treat Long QT Syndrome, Atrial Fibrillation, and resistant and rare cancers. For more information, visit www.thryvtrx.com.

SOURCE Thryv Therapeutics Inc.